IPA for Monica Chi

A number of pharmacologic or genetic interventions have been shown to prevent the development of fibrosis following the intratracheal administration of bleomycin, a commonly used model for the study of lung fibrosis. These studies have provided important mechanistic insights into the development of pulmonary fibrosis and have identified both transforming growth factor-beta (TGF-Beta) and peroxsome prolifeator-activated receptorgamma (PPAR-Gamma) as important mediators of fibrosis. we have shown that preventing the degradation of PPAR-Gamma in response to TGF-Beta impairs the expression of collagen and other profibrotic genes in normal human lung fibroblasts, lung fibroblasts from patients with pulmonary fibrosis, skin fibroblasts from patients with scleroderma and mice treated with bleomycin. In addition, we have generated preliminary data suggesting that TGF-Beta induces mitochondrial reactive oxygen species (ROS), which contribute to the degradation of PPAR-Gamma and are required for a full TGF-Beta transcriptional response. We hypothesize that TGF-Beta-induced mitochondrial ROS via Smad3 activation through the ALK5 receptor. These mitochondrially derived ROS activate downstream kinases and induce the degradation of PPAR-Gamma to amplify the expression of TGF-Beta dependent genes. We propose to test these hypotheses in a series of experiments in vitro, in animal models of acute lung injury/fibrosis and with alveolar fluid from patients with pulmonary fibrosis and ARDS. Aim-1: To determine the mechanism by which TGF-Beta induces the generation of mitochondrial ROS. Aim-2: To determine the mechanism by which mitochondrial ROS modulate TGF-Beta-induced gene transcription. Aim-3: To determine whether fibroblast specific mitochondrial ROS are required for the development of lung fibrosis in murine models and the importance of mitochondrial ROS in TGF-β-mediated gene expression in patients with lung fibrosis. This application represents a highly innovative effort that employs molecular tools in cell culture systems and sophisticated mouse models to elucidate the mechanisms by which mitochondrial ROS regulate the development of pulmonary fibrosis. Our preliminary data support the feasibility of the proposed experiments and provide support for our focus on the TGF-Beta mediated regulation of PPAR-Gamma via induction of mitochondrial ROS. The composition of our research group and all of the proposed experiments are designed to identify novel therapeutic targets for the treatment of lung fibrosis.